Janus kinase (JAK) inhibitors are effective anti-inflammatory agents for treatment of ulcerative colitis (UC).(1) According to drug regulatory agencies and international guidelines, JAK inhibitors should be avoided during pregnancy and lactation.(2-4) The existing evidence on safety of JAK inhibitors during pregnancy is scarce and almost exclusively limited to tofacitinib.(4-7).